Androgen receptor and glucocorticoid receptor modulators

A compound of formula (I):

• wherein:
• R1 is a group selected from:
• a) —COR5,
• b) —COOR5,
• c) —CN, and
• d) —C(O)NH2,
• R5 is a group selected from:
• a) linear or branched C1-C6 alkyl optionally substituted by 1, 2 or 3 substituents selected from —N(R6)R7 and —OR6, halogen atom, C3-C6 cycloalkyl and alkynyl group, and
• b) C3-C6 cycloalkyl,
• R2 is a group selected from:
• a) —COOR8,
• b) —COR8,
• c) —C(O)N(R8)R9,
• d) —CN, and
• e) —S(O)nR8, wherein n is an integer from 1 to 2,
• R8 and R9 are independently selected from:
• a) linear or branched C1-C6 alkyl optionally substituted by 1, 2 or 3 substituents selected from A1 or B2,
• b) A1 group, and
• c) hydrogen atom,
• or
• R8 and R9 together with the nitrogen atom to which they are attached form a 5-6 membered heterocycle which optionally comprises 1 heteroatom selected from O and N, and said heterocycle being optionally substituted by 1 or 2 groups independently selected from linear or branched C1-C4 alkyl,
• R3 is a group selected from:
• a) linear or branched C1-C6 alkyl optionally substituted by 1, 2 or 3 substituents selected from halogen atom, —N(R6)R7, and —OR6,
• R4 is a group selected from:
• a) A1 group,
• b) linear or branched C1-C6 alkyl optionally substituted by 1, 2 or 3 substituents selected from A1 or B2,
• c) —N(R6)R7,
• d) —CN,
• e) —CO—H;
• f) —CO-Me, and
• g) CO—OMe
• X1 and X4 are independently selected from C—B1, N and C—H,
• X2, X3, and X5 are independently selected from C—B1 and C—H,
• A1 is selected from:
• a) C3-C6 cycloalkyl which ring is optionally substituted by 1, 2, 3 or 4 substituents selected from ═O and B3;
• b) a 3 to 6 membered saturated heterocyclyl ring comprising 1, 2 or 3 heteroatoms selected from O, S and N, and which ring is optionally substituted by 1, 2 or 3 substituents selected from ═O and B3;
• and
• c) phenyl or 5 to 6 membered heteroaryl group, either ones are optionally substituted by 1, 2 or 3 substituents selected from B1;
• each B1 is independently selected from halogen atom, —CF3 group, 5 to 6 membered heteroaryl, linear or branched C1-C6 alkyl, —CN, —N(R6)R7, —OR6, —C(═O)R6, —C(═O)OR6, —C(═O)N(R6)R7, —OC(═O)—R6, —N(R6)C(═O)R7, —NR7SO2R6, —SO2N(R6)R7, —SR6, —S(O)R6 and —S(O)2R6,
• each B2 is independently selected from halogen atom, —CN, —N(R6)R7, —OR6, —C(═O)R6, —C(═O)OR6, —C(═O)N(R6)R7, —OC(═O)—R6, —N(R6)C(═O)R7, —NR7SO2R6, —SO2N(R6)R7, —SR6, —S(O)R6, —S(O)2R6, and alkynyl group,
• each B3 is independently selected from halogen atom, linear or branched C1-C6 alkyl, —CN, —N(R6)R7, —OR6, —C(═O)R6, —C(═O)OR6, —C(═O)N(R6)R7, —OC(═O)—R6, —N(R6)C(═O)R7, —NR7SO2R6, —SO2N(R6)R7, —SR6, —S(O)R6, and —S(O)2R6,
• each R6 and R7 independently represents:
• hydrogen atom,
• linear or branched C1-C12 alkyl, C3-C6 cycloalkyl and C4-C6 heterocycloalkyl, which are optionally substituted by 1, 2 or 3 substituents selected from ═O (oxo), halogen atom, hydroxy, phenyl, C3-C6 cycloalkyl, linear or branched C1-C6 alkoxy, amino, alkylamino, dialkylamino, and linear or branched C1-C6 alkylcarbonyl,
• phenyl or 5 to 6 membered heteroaryl group, which are optionally substituted by 1, 2 or 3 substituents selected from halogen atom, cyano group, linear or branched C1-C6 alkyl, linear or branched C1-C6 haloalkyl, hydroxy, linear or branched C1-C6 alkoxy, amino, alkylamino, and dialkylamino;
• R6 and R7 form together with the nitrogen atom to which they are attached, a 3- to 8 membered ring which optionally contains a further heteroatom selected from O, N and S, and which ring is optionally substituted by 1, 2 or 3 substituents selected from ═O (oxo), linear or branched C1-C6 alkyl, linear or branched C1-C6 haloalkyl, and linear or branched C1-C6 alkylcarbonyl;
• with the proviso that when R1 is —COOR5 and R2 is —COOR8 then R4 is not a methyl group, and pharmaceutically acceptable salts thereof.